financetom
Business
financetom
/
Business
/
India Cements post net loss of Rs 75.3 crore in June quarter, revenue at Rs 1,393 crore misses estimate
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
India Cements post net loss of Rs 75.3 crore in June quarter, revenue at Rs 1,393 crore misses estimate
Aug 7, 2023 3:36 AM

Cement maker India Cements registered a net loss of Rs 75.3 crore for the April to June 2023 quarter, marginally lower than the CNBC-TV18 poll projection of Rs 79 crore, the firm’s financial results showed on August 7.

On a sequential basis, however, the company's loss due to irregular monsoon and high raw material costs was lower than Rs 218 crore in the fourth quarter of the financial year 2022-23. On an year-on-year basis, this however, was against a profit of Rs 76.09 crore in the June 2022 ended quarter.

India Cements’ revenue came in at Rs 1,393 crore, about four percent lower than the Rs 1,452 crore prediction of analysts polled by CNBC-TV18. At this level, the revenue from operations is 4.6 percent lower than the Rs 1,460 crore in the previous quarter while the decline was 3.6 percent when compared on a year-on-year basis.

The cement maker’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) was recorded at Rs 5 crore, a significant 64 percent lower than the projection. The firm posted a margin of 0.4 percent for the quarter under review.

Following the first quarter results announcement, India Cements' shares were trading 3.45 percent lower at Rs 216.85 on BSE at 12:55 pm.

India Cements is primarily engaged in the manufacture and marketing of cement and cement-related products. Subsidiaries and associate companies are mainly engaged in the business of sugar, power, financial services, trading, mining and transportation.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Spotify Technology Unusual Options Activity
Spotify Technology Unusual Options Activity
Mar 26, 2024
Investors with a lot of money to spend have taken a bullish stance on Spotify Technology ( SPOT ) . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this...
Palisades Goldcorp Reports Renewal of Normal Course Issuer Bid
Palisades Goldcorp Reports Renewal of Normal Course Issuer Bid
Mar 26, 2024
01:46 PM EDT, 03/26/2024 (MT Newswires) -- Palisades Goldcorp Ltd. ( PLGDF ) on Tuesday rose 2.2% on last look after reporting that it has secured approval from the TSX Venture Exchange for the company's plan to renew its normal course issuer bid for common shares through the facilities of the TSX-V. Effective April 1, the renewal allows the company...
UK's DS Smith in deal talks with International Paper
UK's DS Smith in deal talks with International Paper
Mar 26, 2024
March 26 (Reuters) - Paper and packaging company DS Smith ( DITHF ) said on Tuesday that it is in discussions with U.S.-listed International Paper ( IP ) regarding a proposal to buy the British packaging firm through a possible all-share offer. Under the terms of the proposal, DS Smith ( DITHF ) shareholders would receive 0.1285 shares in International...
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly
Mar 26, 2024
Monday, Biohaven’s CEO, Vlad Coric, joined CNBC Fast Money to discuss the weight loss drug wars and the company’s experimental obesity drug. Biohaven ( BHVN ) said it is developing an obesity drug that works differently from Novo Nordisk A/S’s and Eli Lilly And Co’s popular GLP-1 drugs. The experimental obesity drug, dubbed taldefgrobep alfa (BHVN-2000), could prevent muscle loss while helping shed weight. The company highlights that 20%-50%...
Copyright 2023-2026 - www.financetom.com All Rights Reserved